Items where authors include "Helliwell, P."

Article

De Lorenzis, E. orcid.org/0000-0001-9819-105X, Kakkar, V., Di Donato, S. et al. (13 more authors) (2024) Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. RMD Open, 10 (1). e003216. ISSN 2056-5933

Coyle, C., Watson, L., Whately-Smith, C. et al. (28 more authors) (2024) How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology. kead679. ISSN 1462-0324

Hailey, L., Bundy, C., Burstow, H. et al. (13 more authors) (2023) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Mease, P. orcid.org/0000-0002-6620-0457, Helliwell, P. orcid.org/0000-0002-4155-9105, Silwinska‐Stanczyk, P. et al. (12 more authors) (2023) Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis & Rheumatology, 75 (8). pp. 1370-1380. ISSN 2326-5191

Hailey, L. orcid.org/0000-0001-5769-8663, Bundy, C., Burstow, H. et al. (13 more authors) (2022) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Madan, J., Ades, T., Barton, P. et al. (9 more authors) (2015) Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2 (2). pp. 113-125. ISSN 2198-6576

Gilworth, G., Emery, P., Barkham, N. et al. (3 more authors) (2009) Reducing work disability in Ankylosing Spondylitis -development of a work instability scale for AS. BMC Musculoskeletal Disorders , 10. ISSN 1471-2474

Firth, J., Hale, C., Helliwell, P. et al. (2 more authors) (2008) The prevalence of foot ulceration in patients with rheumatoid arthritis. Arthritis Care & Research, 59 (2). pp. 200-205.

Conference or Workshop Item

Watson, L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) Current prescribing practices in psoriatic arthritis - comparison between the UK and Europe. In: British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester - Hybrid.

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, PA.

Proceedings Paper

Coyle, C., Watson, L., Brooke, M. et al. (25 more authors) (2023) P174 Psoriatic arthritis patients in the UK have a lower quality of life than patients in mainland Europe - an analysis from the ASSIST study. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Watson, L.L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) P179 Shared decision-making in psoriatic arthritis consultations. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.

Coyle, C., Whately-Smith, C., Brooke, M. et al. (24 more authors) (2022) 1028: How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA? In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2040-2042.

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) 1268: Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2488-2490.

Yazji, S., Helliwell, P., Balanescu, A. et al. (13 more authors) (2022) 1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2954-2957.

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. , pp. 4182-4184.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4214-4216.

Tillett, W., Coates, L., Sharaf, M. et al. (7 more authors) (2022) 2142: Strong Correlation Between Short- vs Long-form Composite Measures ofPsoriatic Arthritis Disease Activity in a TNFi-IR Population Treated withGuselkumab: Data from the Phase 3b COSMOS Trial. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4248-4251.

Gladman, D.D., Mease, P.J., Bird, P. et al. (13 more authors) (2022) AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1574-1575.

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) AB0904 Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1580-1581.

Mulder, M.L.M., Vriezekolk, J.E., Van Hal, T. et al. (7 more authors) (2022) POS0078 Comparing Methotrexate Monotherapy With Methotrexate Plus Leflunomide Combination Therapy In Psoriatic Arthritis: A Randomised, Placebo-Controlled, Double-Blind Clinical Trial (Complete-PsA). In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , p. 259.

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 818-819.

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 832-833.

Tillett, W., Coates, L., Neuhold, M. et al. (6 more authors) (2022) POS1043 Strong Correlation Between Short- Vs Long-Form Composite Measures Of Psoriatic Arthritis Disease Activity In A TNFi-IR Population Treated With Guselkumab: Data From The Phase 3b Cosmos Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 838-839.

Preprint

Dand, N. orcid.org/0000-0002-1805-6278, Stuart, P.E., Bowes, J. et al. (82 more authors) (2023) GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. [Preprint]